Susan Ruth Marengo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Susan Ruth Marengo has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ailin Zhang
Pharmaceutical College Tianjin Medical University Tianjin China
1 shared publication Andre J. Sommer
Department of Chemistry and Biochemistry, Miami University, Oxford, USA
1 shared publication- Andrea Romani
Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-4970, USA
1 shared publication Andrew P. Evan
Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, USA
1 shared publicationDaniel H. -C. Chen
Department of Urology, School of Medicine, Case Western Reserve University, Cleveland, USA
1 shared publicationDonald G. Ferguson
Department of Anatomy, School of Medicine, Case Western Reserve University, Cleveland, USA
1 shared publication
Latest Publications
- 16 October 2008
- Published by Springer Nature in Urological Research
- Vol. 36 (6) , 319-326
Partitioning of 14C-oxalate excretion in rats during a persistent oxalate challenge
This study was done to resolve published discrepancies in oxalate excretion between humans and rats and to characterize oxalate partitioning in rats during persistent severe hyperoxaluria, such as that seen in many bariatric patients. Osmotic minipumps dispensing 360 μmole/day KOx + 3.9 ± 0.14 μCi/day 14C-oxalate were implanted subcutaneously. All excreta were collected. Rats were killed on day 13 and carcasses were dissected, ground, dissolved in HCl, and subjected to scintillation counting, and 92.1 ± 3.9% of total oxalate administered was recovered. This was partitioned among the skin complex (38.2 ± 7.7%), carcass complex (24.5 ± 5.9%), and excreta (29.5 ± 1.9%). The distribution of oxalate in the skin and carcass complexes led us to infer that only 29.5 ± 1.9% of the administered oxalate entered the circulation. Of the circulated oxalate, 98.4 ± 0.4% was excreted (total urine 78.9 ± 1.7%; raw feces 21.0 ± 1.7%). Thus, most oxalate that does enter the circulation is promptly excreted in rats, as in humans. Consequently, even after a large, persistent oxalate challenge, very little oxalate had accumulated in the internal organs, muscle, and skeleton. Unlike humans, however, rats excrete a significant fraction of oxalate in the feces.
- 16 October 2008
- Published by Springer Nature in Urological Research
- Vol. 36 (6) , 319-326
Partitioning of 14C-oxalate excretion in rats during a persistent oxalate challenge
This study was done to resolve published discrepancies in oxalate excretion between humans and rats and to characterize oxalate partitioning in rats during persistent severe hyperoxaluria, such as that seen in many bariatric patients. Osmotic minipumps dispensing 360 μmole/day KOx + 3.9 ± 0.14 μCi/day 14C-oxalate were implanted subcutaneously. All excreta were collected. Rats were killed on day 13 and carcasses were dissected, ground, dissolved in HCl, and subjected to scintillation counting, and 92.1 ± 3.9% of total oxalate administered was recovered. This was partitioned among the skin complex (38.2 ± 7.7%), carcass complex (24.5 ± 5.9%), and excreta (29.5 ± 1.9%). The distribution of oxalate in the skin and carcass complexes led us to infer that only 29.5 ± 1.9% of the administered oxalate entered the circulation. Of the circulated oxalate, 98.4 ± 0.4% was excreted (total urine 78.9 ± 1.7%; raw feces 21.0 ± 1.7%). Thus, most oxalate that does enter the circulation is promptly excreted in rats, as in humans. Consequently, even after a large, persistent oxalate challenge, very little oxalate had accumulated in the internal organs, muscle, and skeleton. Unlike humans, however, rats excrete a significant fraction of oxalate in the feces.
- 3 June 2008
- Published by Springer Nature in Nature Clinical Practice Nephrology
- Vol. 4 (7) , 368-377
Oxalate in renal stone disease: the terminal metabolite that just won't go away
Nature Clinical Practice Nephrology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international Advisory Board will ensure comprehensive coverage of topical issues throughout the year, with the highest standards of editorial quality and integrity that are hallmarks of Nature Publishing Group.
- 3 June 2008
- Published by Springer Nature in Nature Clinical Practice Nephrology
- Vol. 4 (7) , 368-377
Oxalate in renal stone disease: the terminal metabolite that just won't go away
Nature Clinical Practice Nephrology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international Advisory Board will ensure comprehensive coverage of topical issues throughout the year, with the highest standards of editorial quality and integrity that are hallmarks of Nature Publishing Group.
- 1 April 2008
- Published by Elsevier in Animal Reproduction Science
- Vol. 105 (1-2) , 52-63
Maturing the sperm: Unique mechanisms for modifying integral proteins in the sperm plasma membrane
- 1 April 2008
- Published by Elsevier in Animal Reproduction Science
- Vol. 105 (1-2) , 52-63
Maturing the sperm: Unique mechanisms for modifying integral proteins in the sperm plasma membrane
- 15 February 2006
- Published by Springer Nature in Urological Research
- Vol. 34 (3) , 200-210
Continuous infusion of oxalate by minipumps induces calcium oxalate nephrocalcinosis
It is hypothesized that oxalate plays an active role in calcium oxalate (CaOx) nephrocalcinosis and oxalate driven nephrolithiasis by interacting with the kidney. We developed an adjustable, nonprecursor, continuous infusion model of hyperoxaluria and CaOx nephrocalcinosis to investigate this hypothesis. Minipumps containing PBS or KOx (60–360 μmol/day; n=5–7/dose) were implanted subcutaneously in male Sprague–Dawley rats on D0 and D6. Rats were killed on D13. Oxalate excretion and CaOx crystalluria were monitored by 20+4 h urine collections. Localization and content of intrarenal crystals were determined on frozen sections using polarization and μFTIR. Oxalate excretion was significantly elevated in all KOx rats (P≤0.005). CaOx crystalluria was most persistent in the 240–360 μmol/day KOx rats, but even 60 μmol/day KOx rats showed sporadic crystalluria. One hundred percent of KOx rats had CaOx nephrocalcinosis as confirmed by μFTIR. Most crystals were localized to the lumens of the corticomedullary collecting ducts. A few crystals are localized just under the papillar urothelium. The minipump model is the first model of hyperoxaluria to provide continuous infusion of oxalate. It permits control of the levels of hyperoxaluria, crystalluria and CaOx nephrocalcinosis. The level of sustained hyperoxaluria and CaOx nephrocalcinosis induced by treatment with 360 μmol/day KOx for 13D models the conditions frequently observed in jejunoileal bypass patients. Adjustments in the length of treatment and level of hyperoxaluria may allow this model to also be used to study the oxalate driven CaOx-nephrolithiasis common in patients with hyperoxaluria due to other causes.
- 15 February 2006
- Published by Springer Nature in Urological Research
- Vol. 34 (3) , 200-210
Continuous infusion of oxalate by minipumps induces calcium oxalate nephrocalcinosis
It is hypothesized that oxalate plays an active role in calcium oxalate (CaOx) nephrocalcinosis and oxalate driven nephrolithiasis by interacting with the kidney. We developed an adjustable, nonprecursor, continuous infusion model of hyperoxaluria and CaOx nephrocalcinosis to investigate this hypothesis. Minipumps containing PBS or KOx (60–360 μmol/day; n=5–7/dose) were implanted subcutaneously in male Sprague–Dawley rats on D0 and D6. Rats were killed on D13. Oxalate excretion and CaOx crystalluria were monitored by 20+4 h urine collections. Localization and content of intrarenal crystals were determined on frozen sections using polarization and μFTIR. Oxalate excretion was significantly elevated in all KOx rats (P≤0.005). CaOx crystalluria was most persistent in the 240–360 μmol/day KOx rats, but even 60 μmol/day KOx rats showed sporadic crystalluria. One hundred percent of KOx rats had CaOx nephrocalcinosis as confirmed by μFTIR. Most crystals were localized to the lumens of the corticomedullary collecting ducts. A few crystals are localized just under the papillar urothelium. The minipump model is the first model of hyperoxaluria to provide continuous infusion of oxalate. It permits control of the levels of hyperoxaluria, crystalluria and CaOx nephrocalcinosis. The level of sustained hyperoxaluria and CaOx nephrocalcinosis induced by treatment with 360 μmol/day KOx for 13D models the conditions frequently observed in jejunoileal bypass patients. Adjustments in the length of treatment and level of hyperoxaluria may allow this model to also be used to study the oxalate driven CaOx-nephrolithiasis common in patients with hyperoxaluria due to other causes.